# Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

> **NCT00298272** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 54 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** IDEC-C2B8 (rituximab)
- **DRUG:** Placebo
- **DRUG:** Methotrexate
- **DRUG:** Etanercept
- **DRUG:** Adalimumab
- **DRUG:** Methylprednisolone
- **DIETARY_SUPPLEMENT:** Folate

## Key facts

- **NCT ID:** NCT00298272
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-04
- **Final completion:** 2011-07
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Sponsor decided to end long term extension phase for business reasons unrelated to safety.
- **Last updated:** 2015-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298272, "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00298272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*